Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Impact on Recurrence in Breast Cancer
NCT03109990Completed
- Sponsor
- Renji Hospital
- Start
- May 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine in breast cancer (2 arms), sponsored by Renji Hospital. Primary endpoint: Study Feasibility. Started May 2016; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03109990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109990.